MOORE JOHN R
SEC CIK 1191702 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| EWTX | Edgewise Therapeutics, Inc. | GC | 22.7K | — | $4.45M | 34 | 2021-12-28 | 2026-08-12 |
Most active insiders at EWTX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Russell Alan J | CSO, Dir | — | $10.25M |
| 2 | Donovan Joanne M. | CMO | — | $4.62M |
| 3 | Edris Badreddin | Dir | — | $3.40M |
| 4 | KOCH KEVIN | Pres, CEO, Dir | — | $785.0K |
| 5 | Derakhshan Behrad | Chief Business Off | — | $223.4K |
| 6 | MOORE JOHN R | GC | — | $219.8K |
| 7 | Fox Jonathan C | Dir | $199.4K | — |
Transactions 34
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-08-14 16:53 | 2026-08-12 | EWTX | Edgewise Therapeutics, Inc. | MOORE JOHN R | GC | M - OptEx | $0.00 | +12.5K | 22.7K | +122% | $0 |
| DM | 2026-08-14 16:53 | 2026-08-12 | EWTX | Edgewise Therapeutics, Inc. | MOORE JOHN R | GC | S - Sale+OE | $43.82 | -5,016 | 17.7K | -22% | -$219.8K |
| D | 2025-08-14 | 2025-08-12 | EWTX | Edgewise Therapeutics, Inc. | MOORE JOHN R | GC | S - Sale+OE | $13.39 | -2,098 | 10.2K | -17% | -$28.1K |
| D | 2025-08-14 | 2025-08-12 | EWTX | Edgewise Therapeutics, Inc. | MOORE JOHN R | GC | M - OptEx | $0.00 | +5,781 | 12.3K | +89% | $0 |
| D | 2025-05-07 | 2025-05-02 | EWTX | Edgewise Therapeutics, Inc. | MOORE JOHN R | GC | S - Sale+OE | $16.45 | -1,930 | 6,531 | -23% | -$31.7K |
| D | 2025-05-07 | 2025-05-01 | EWTX | Edgewise Therapeutics, Inc. | MOORE JOHN R | GC | M - OptEx | $0.00 | +5,209 | 8,461 | +160% | $0 |
| DM | 2024-09-24 | 2024-09-20+ | EWTX | Edgewise Therapeutics, Inc. | MOORE JOHN R | GC | M - OptEx | $0.71 | +70.9K | 53.3K | New | +$50.4K |
| DM | 2024-09-24 | 2024-09-20+ | EWTX | Edgewise Therapeutics, Inc. | MOORE JOHN R | GC | S - Sale+OE | $28.15 | -70.9K | 3,252 | -96% | -$2.00M |
| D | 2024-05-03 | 2024-05-01 | EWTX | Edgewise Therapeutics, Inc. | MOORE JOHN R | GC | M - OptEx | $0.00 | +5,208 | 5,208 | New | $0 |
| D | 2024-05-03 | 2024-05-02 | EWTX | Edgewise Therapeutics, Inc. | MOORE JOHN R | GC | S - Sale+OE | $18.91 | -1,956 | 3,252 | -38% | -$37.0K |
| DMT | 2024-02-09 | 2024-02-07+ | EWTX | Edgewise Therapeutics, Inc. | MOORE JOHN R | GC | M - OptEx | $1.93 | +29.8K | 3,813 | New | +$57.6K |
| DMT | 2024-02-09 | 2024-02-07+ | EWTX | Edgewise Therapeutics, Inc. | MOORE JOHN R | GC | S - Sale+OE | $20.00 | -29.8K | 0 | -100% | -$596.8K |
| 2023-12-28 | 2023-12-27 | EWTX | Edgewise Therapeutics, Inc. | MOORE JOHN R | GC | S - Sale | $10.50 | -8,497 | 0 | -100% | -$89.2K | |
| D | 2023-05-03 | 2023-05-01 | EWTX | Edgewise Therapeutics, Inc. | MOORE JOHN R | GC | M - OptEx | $0.00 | +5,208 | 8,462 | +160% | $0 |
| D | 2023-05-03 | 2023-05-02 | EWTX | Edgewise Therapeutics, Inc. | MOORE JOHN R | GC | S - Sale+OE | $8.90 | -1,897 | 6,565 | -22% | -$16.9K |
| D | 2022-10-05 | 2022-10-03 | EWTX | Edgewise Therapeutics, Inc. | MOORE JOHN R | GC | S - Sale+OE | $9.76 | -4,730 | 3,000 | -61% | -$46.2K |
| D | 2022-10-05 | 2022-10-03 | EWTX | Edgewise Therapeutics, Inc. | MOORE JOHN R | GC | M - OptEx | $1.93 | +4,730 | 7,730 | +158% | +$9,129 |
| D | 2022-09-08 | 2022-09-06 | EWTX | Edgewise Therapeutics, Inc. | MOORE JOHN R | GC | M - OptEx | $1.93 | +4,730 | 7,730 | +158% | +$9,129 |
| DM | 2022-09-08 | 2022-09-06 | EWTX | Edgewise Therapeutics, Inc. | MOORE JOHN R | GC | S - Sale+OE | $10.91 | -4,730 | 3,000 | -61% | -$51.6K |
| DM | 2022-08-05 | 2022-08-03 | EWTX | Edgewise Therapeutics, Inc. | MOORE JOHN R | GC | M - OptEx | $1.34 | +9,232 | 7,730 | New | +$12.3K |
| D | 2022-08-05 | 2022-08-03 | EWTX | Edgewise Therapeutics, Inc. | MOORE JOHN R | GC | S - Sale+OE | $9.31 | -9,232 | 3,000 | -75% | -$85.9K |
| DM | 2022-07-07 | 2022-07-05+ | EWTX | Edgewise Therapeutics, Inc. | MOORE JOHN R | GC | S - Sale+OE | $8.37 | -9,232 | 3,000 | -75% | -$77.3K |
| DM | 2022-07-07 | 2022-07-05+ | EWTX | Edgewise Therapeutics, Inc. | MOORE JOHN R | GC | M - OptEx | $1.34 | +9,232 | 4,046 | New | +$12.3K |
| DM | 2022-06-21 | 2022-06-16+ | EWTX | Edgewise Therapeutics, Inc. | MOORE JOHN R | GC | M - OptEx | $1.69 | +67.9K | 16.5K | New | +$114.6K |
| DM | 2022-06-21 | 2022-06-16+ | EWTX | Edgewise Therapeutics, Inc. | MOORE JOHN R | GC | S - Sale+OE | $6.83 | -67.9K | 3,000 | -96% | -$463.9K |
| DM | 2022-06-15 | 2022-06-13+ | EWTX | Edgewise Therapeutics, Inc. | MOORE JOHN R | GC | M - OptEx | $0.7371 | +26.4K | 21.7K | New | +$19.4K |
| DM | 2022-06-15 | 2022-06-13+ | EWTX | Edgewise Therapeutics, Inc. | MOORE JOHN R | GC | S - Sale+OE | $6.08 | -26.4K | 3,000 | -90% | -$160.5K |
| DM | 2022-06-10 | 2022-06-08+ | EWTX | Edgewise Therapeutics, Inc. | MOORE JOHN R | GC | M - OptEx | $0.71 | +27.3K | 10.6K | New | +$19.4K |
| DM | 2022-06-10 | 2022-06-08+ | EWTX | Edgewise Therapeutics, Inc. | MOORE JOHN R | GC | S - Sale+OE | $6.44 | -27.3K | 3,000 | -90% | -$175.8K |
| DM | 2022-06-07 | 2022-06-03+ | EWTX | Edgewise Therapeutics, Inc. | MOORE JOHN R | GC | S - Sale+OE | $6.26 | -47.3K | 3,000 | -94% | -$296.0K |
| DM | 2022-06-07 | 2022-06-03+ | EWTX | Edgewise Therapeutics, Inc. | MOORE JOHN R | GC | M - OptEx | $1.49 | +47.3K | 16.9K | New | +$70.3K |
| 2022-05-18 | 2022-05-16 | EWTX | Edgewise Therapeutics, Inc. | MOORE JOHN R | GC | S - Sale | $7.42 | -10.8K | 3,000 | -78% | -$80.1K | |
| D | 2022-01-25 | 2022-01-21 | EWTX | Edgewise Therapeutics, Inc. | MOORE JOHN R | GC | M - OptEx | $0.71 | +5,400 | 12.4K | +78% | +$3,834 |
| D | 2021-12-30 | 2021-12-28 | EWTX | Edgewise Therapeutics, Inc. | MOORE JOHN R | GC | M - OptEx | $0.71 | +5,400 | 6,962 | +346% | +$3,834 |
Purchase Sale Sale after option exercise All abbreviations